Hepatic Outcomes of Nonalcoholic Fatty Liver Disease Including Cirrhosis and Hepatocellular Carcinoma
Copyright © 2023 Elsevier Inc. All rights reserved..
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide and represents a significant cause of cirrhosis and hepatocellular carcinoma (HCC). Almost 20% of patients with NAFLD and advanced fibrosis develop cirrhosis, of which 20% can progress to decompensated liver stage. Although patients with cirrhosis or fibrosis continue to have a high risk for HCC progression, growing evidence shows that NAFLD-HCC can develop even in the absence of cirrhosis. Current evidence characterizes NAFLD-HCC primarily as a condition with late presentation, lower response to curative therapy, and poor prognosis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Clinics in liver disease - 27(2023), 2 vom: 06. Mai, Seite 211-223 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Alqahtani, Saleh A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Fatty liver |
|---|
| Anmerkungen: |
Date Completed 10.04.2023 Date Revised 22.04.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.cld.2023.01.019 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355288710 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355288710 | ||
| 003 | DE-627 | ||
| 005 | 20231226064032.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cld.2023.01.019 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1184.xml |
| 035 | |a (DE-627)NLM355288710 | ||
| 035 | |a (NLM)37024203 | ||
| 035 | |a (PII)S1089-3261(23)00019-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Alqahtani, Saleh A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hepatic Outcomes of Nonalcoholic Fatty Liver Disease Including Cirrhosis and Hepatocellular Carcinoma |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.04.2023 | ||
| 500 | |a Date Revised 22.04.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Inc. All rights reserved. | ||
| 520 | |a Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide and represents a significant cause of cirrhosis and hepatocellular carcinoma (HCC). Almost 20% of patients with NAFLD and advanced fibrosis develop cirrhosis, of which 20% can progress to decompensated liver stage. Although patients with cirrhosis or fibrosis continue to have a high risk for HCC progression, growing evidence shows that NAFLD-HCC can develop even in the absence of cirrhosis. Current evidence characterizes NAFLD-HCC primarily as a condition with late presentation, lower response to curative therapy, and poor prognosis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Fatty liver | |
| 650 | 4 | |a Hepatocellular carcinoma | |
| 650 | 4 | |a Liver cancer | |
| 650 | 4 | |a Liver cirrhosis | |
| 650 | 4 | |a Nonalcoholic fatty liver | |
| 650 | 4 | |a Nonalcoholic steatohepatitis | |
| 700 | 1 | |a Chan, Wah-Kheong |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Ming-Lung |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinics in liver disease |d 1997 |g 27(2023), 2 vom: 06. Mai, Seite 211-223 |w (DE-627)NLM096493259 |x 1557-8224 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2023 |g number:2 |g day:06 |g month:05 |g pages:211-223 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cld.2023.01.019 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2023 |e 2 |b 06 |c 05 |h 211-223 | ||